论文部分内容阅读
目的评价赖诺普利(商品名帝益络)对舒张性心力衰竭(DHF)的临床疗效及安全性,方法将42例DHF患者随机分成治疗组21例及对照组2l例,两组患者均给予抗DHF的常规治疗,治疗组患者加用赖诺普利10-20mg/d,疗程4～6个月。疗程结束后,两组患者对比治疗前后临床症状及左心室超声舒张功能指标改善情况。结果(1)治疗组患者在治疗后临床症状明显改善(71.4%比43.0%,P<0.01),左心室舒张功能指标亦优于治疗前(P<0.05～0.01),而对照组患者治疗前后无明显差异(P>0.05);(2)治疗过程中,治疗组发生低血压3例(14.3%)干咳2例(9.5%),血肌酐轻度升高1例4.8%,结论赖诺普利治疗DHF是安全有效的,有利于改善患者的预后。
Objective To evaluate the clinical efficacy and safety of lisinopril in patients with diastolic heart failure (DHF). Methods Forty-two patients with DHF were randomly divided into treatment group (21 cases) and control group (21 cases) Given conventional anti-DHF treatment, patients in the treatment group plus lisinopril 10-20mg / d, treatment of 4 to 6 months. After the course of treatment, the two groups of patients were compared before and after treatment of clinical symptoms and left ventricular echocardiography to improve diastolic function. Results (1) The clinical symptoms of the treatment group were significantly improved after treatment (71.4% vs. 43.0%, P <0.01), and the left ventricular diastolic function index was also better than before treatment (P <0.05-0.01) (2) In the course of treatment, there were 3 cases (14.3%) with hypotension in the treatment group, 2 cases (9.5%) with dry cough, and mild increase in serum creatinine (4.8%) in 1 case Lee treatment of DHF is safe and effective, help to improve the prognosis of patients.